Alembic Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 120% at ₹2.4/Share	04-Aug-2026	04-Aug-2026
DividendsFinal Dividend of 120% at ₹2.4/Share	05-Aug-2025	05-Aug-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
HDFC BSE REITS and Commercial Real Estate Index Fund - Regular Plan - Growth	-	7.08 k (100%)
Motilal Oswal BSE 1000 Index Fund - Regular Plan - Growth	198	197 (0.51%)

Manjushri Sharma SEBI RA

30 Sep • 11:07 PM · SEBI-Registered Analyst

Alembic Limited: Promoter Group Buys Shares

ALEMBICLTD

Limited (ALEMBICLTD) witnessed a notable promoter group transaction with Nirayu Private Limited purchasing shares through a market purchase during 28 September to 29 September 2026. According to the disclosed transaction details Nirayu Private Limited acquired 74 554 shares of Alembic Limited at an average price of ₹106.96 per share. The total value of the transaction stood at approximately ₹79.75 lakh. Following the purchase the promoter group holding increased from 63.55% to 63.58%. This represents an increase of 0.03 percentage points in the disclosed holding. Promoter group transactions are closely watched by market participants because changes in promoter ownership can provide additional information about shareholder activity. A promoter group purchase may indicate an increase in ownership exposure. However investors should not interpret a single transaction as a standalone signal for the future direction of the stock. For Alembic Limited investors can track further promoter group transactions along with shareholding disclosures and the company's financial and operational developments. Monitoring whether additional purchases take place can provide greater context around the change in promoter ownership. The transaction was disclosed on 30 September 2026 and involved a market purchase by Nirayu Private Limited. Disclosure: This content is for informational purposes only and should not be construed as investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consider their individual risk profile and financial circumstances before making investment decisions.

Vivek kumar

25 Sep • 10:55 PM · SEBI-Registered Analyst

Alembic Pharmaceuticals breaks out of consolidation!

Alembic Pharmaceuticals breaks out of consolidation Alembic Pharmaceuticals Limited (NSE: ALEMBICLTD) is trading around ₹850 after breaking above a tight consolidation range and a sloping trendline. Why it matters The breakout has been accompanied by strong volume participation, with recent volumes consistently building above the 20-day average. The stock is also trading above its short-, medium- and long-term moving averages. The technical setup is currently close to the breakout retest zone. This makes the ability to hold the breakout area important for the next leg of the move. Technical analyst Jay Mehta of JM Financial Services has published ₹900 and ₹999 as targets, with ₹786 as the stop-loss level. These are analyst-published levels, not my independent price targets. My view

Kundan Motwani

25 Sep • 4:00 PM · SEBI-Registered Analyst

HBL Engineering Recent setup: broke out candidate

HBLENGINE

HBL Engineering Recent setup: broke out of a consolidation range and trendline with strong volume. Reference price: ₹775.30 Upside levels cited by JM Financial: ₹809 and ₹830 Risk level cited: ₹735 The broader market was weak on Sept 24, so a breakout should ideally be confirmed by volume rather than chased at the open. Other current breakout/momentum setups worth watching: Inventurus Knowledge Solutions: ₹1,868 → ₹2,050/₹2,150; SL ₹1,785. Alembic Pharma: ₹850 → ₹900/₹999; SL ₹786. Finolex Cables: ₹1,480 → ₹1,600; SL ₹1,400. Important: These are technical setups reported by analysts, not a guaranteed “tomorrow breakout.” For Monday, I'd wait for the first 15–30 minutes and look for price + volume confirmation.

Covesting Technologies Pvt Ltd

21 Sep • 7:35 PM · SEBI-Registered Analyst

Alembic Pharmaceuticals breaks above its ₹840 range!

Alembic Pharmaceuticals breaks above its ₹840 range Alembic Pharmaceuticals Limited (NSE: APL) was trading at ₹845.75 in the September 21 technical setup. The stock had spent the previous couple of months consolidating between ₹800 and ₹840 before delivering a price-volume breakout above the range. The breakout came with the highest volume of the previous 10 trading sessions. Bollinger Bands have also started expanding after a period of contraction, while the daily momentum indicator recorded a positive crossover. The move above ₹840 changes the immediate chart structure from consolidation to a potential continuation phase. The expansion in Bollinger Bands and higher volume provide additional confirmation of the price move. My view is that ₹840 is now the key technical reference. If the stock sustains above this previous range ceiling, the breakout structure remains intact. A move back below the ₹825 area would weaken the setup.

Finkhoz Roboadvisory Services

17 Sep • 9:58 AM · SEBI-Registered Analyst

Key stock triggers put these names in focus today

Several stocks are in focus on September 17 following key corporate developments. Tempsens Instruments India reported Q1 consolidated revenue growth of 33.4% YoY to ₹118.7 crore, while profit rose 14.2% to ₹15.2 crore, highlighting healthy business momentum. Highway Infrastructure received a ₹220.66 crore order from Uttar Pradesh Expressways Industrial Development Authority for toll collection and operations on the Gorakhpur Link Expressway. Alembic Pharmaceuticals received an Establishment Inspection Report from the USFDA, closing the inspection of its bioequivalence facility in Vadodara.

MAZDOCK

Dock Shipbuilders signed an MoU to participate as an anchor shipyard in a proposed greenfield shipbuilding cluster in Maharashtra. Meanwhile, Fortis Healthcare signed agreements to provide healthcare services at a 400+ bed super-specialty hospital in New Delhi, while G R Infraprojects issued a termination notice to NTPC for a BESS project. For investors, earnings momentum, order wins, regulatory clearances and project execution will remain key triggers. However, order conversion, execution timelines and margin performance should be monitored before assessing the longer-term impact of these developments.

Akhilesh Jat SEBI RA

17 Sep • 8:02 AM · SEBI-Registered Analyst

Alembic Pharma in Focus After USFDA EIR Clearance

Alembic Pharmaceuticals Limited (

APLLTD

) is in focus after the USFDA issued an Establishment Inspection Report (EIR) and closed the inspection of the company's bioequivalence facility in Vadodara, Gujarat. The development removes a regulatory overhang and reinforces the facility's compliance status. For pharmaceutical companies with exposure to the US market, regulatory clearances are closely watched as they support business continuity and future product opportunities. Alembic Pharmaceuticals derives a meaningful portion of its business from international generics and APIs, making USFDA-related developments important for investor sentiment. While the regulatory update is positive, the stock has yet to reflect a decisive directional move. Over the past two and a half months, Alembic Pharmaceuticals has largely traded within the ₹790–₹855 range, despite previously forming an Inverse Head & Shoulders pattern. The prolonged consolidation near the neckline suggests that market participants are awaiting a stronger trigger before committing to a sustained trend. A sustained move above ₹860, supported by rising volumes and preferably two consecutive daily closes above the level, could indicate strengthening momentum. On the downside, a break below ₹787 would weaken the recent higher-high, higher-low structure and warrant caution. The USFDA development is fundamentally positive, but the technical setup remains range-bound. For now, ₹860 on the upside and ₹787 on the downside remain the key levels that could determine the stock's next meaningful move. Disclosure: Neither I nor my family members hold any position in the mentioned scrip. This content is shared solely for informational and educational purposes and should not be construed as investment advice or a recommendation to buy or sell.

Alembic Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Alembic Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Alembic Ltd.?

What is the market cap of Alembic Ltd.?

Should I buy Alembic Ltd. stock now?

What is the 52 week high and low of Alembic Ltd.?

Is the Alembic Ltd. stock good to buy?

Is Alembic Ltd. a good buy for the long term?

Is Alembic Ltd. overvalued or undervalued?

What is the PE and PB ratio of Alembic Ltd.?